Full results from the Phase III ARAMIS trial of Nubeqa (darolutamide) have been published in The New England Journal of Medicine.
Nubeqa is an oral androgen receptor inhibitor (ARi) under development by German pharma major Bayer (BAYN: DE) and originator Orion Corp (Nasdaq: OMX), from Finland.
Results from ARAMIS, which were presented at the annual congress of the American Society of Clinical Oncology (ASCO) in May 2020, show a positive impact on overall survival (OS) in non-metastatic castration-resistant prostate cancer (nmCRPC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze